Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

NCT03262545 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT03262545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
August 27, 2017
Completion date
February 28, 2021
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiogenesis inhibitors，ovarian neoplasms